HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies.

AbstractBACKGROUND:
Individual studies have suggested that some circulating fatty acids are associated with prostate cancer risk, but have not been large enough to provide precise estimates of associations, particularly by stage and grade of disease.
METHODS:
Principal investigators of prospective studies on circulating fatty acids and prostate cancer were invited to collaborate. Investigators provided individual participant data on circulating fatty acids (weight percent) and other characteristics of prostate cancer cases and controls. Prostate cancer risk by study-specific fifths of 14 fatty acids was estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.
RESULTS:
Five thousand and ninety-eight case patients and 6649 control patients from seven studies with an average follow-up of 5.1 (SD = 3.3) years were included. Stearic acid (18:0) was inversely associated with total prostate cancer (odds ratio [OR] Q5 vs Q1 = 0.88, 95% confidence interval [CI] = 0.78 to 1.00, P trend = .043). Prostate cancer risk was, respectively, 14% and 16% greater in the highest fifth of eicosapentaenoic acid (20:5n-3) (OR = 1.14, 95% CI = 1.01 to 1.29, Ptrend = .001) and docosapentaenoic acid (22:5n-3) (OR = 1.16, 95% CI = 1.02 to 1.33, P trend = .003), but in each case there was heterogeneity between studies (P = .022 and P < .001, respectively). There was heterogeneity in the association between docosapentaenoic acid and prostate cancer by grade of disease (P = .006); the association was statistically significant for low-grade disease but not high-grade disease. The remaining 11 fatty acids were not statistically associated with total prostate cancer risk.
CONCLUSION:
There was no strong evidence that circulating fatty acids are important predictors of prostate cancer risk. It is not clear whether the modest associations of stearic, eicosapentaenoic, and docosapentaenoic acid are causal.
AuthorsFrancesca L Crowe, Paul N Appleby, Ruth C Travis, Matt Barnett, Theodore M Brasky, H Bas Bueno-de-Mesquita, Veronique Chajes, Jorge E Chavarro, Maria-Dolores Chirlaque, Dallas R English, Robert A Gibson, Graham G Giles, Gary E Goodman, Susanne M Henning, Rudolf Kaaks, Irena B King, Lawrence N Kolonel, Alan R Kristal, Marian L Neuhouser, Song-Yi Park, Gianluca Severi, Afshan Siddiq, Meir J Stampfer, Pär Stattin, Catherine M Tangen, Anne Tjønneland, Dimitrios Trichopoulos, Rosario Tumino, Lynne R Wilkens, Timothy J Key, Naomi E Allen, Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 106 Issue 9 (Sep 2014) ISSN: 1460-2105 [Electronic] United States
PMID25210201 (Publication Type: Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Copyright© The Author 2014. Published by Oxford University Press.
Chemical References
  • Fatty Acids
  • Fatty Acids, Unsaturated
  • Stearic Acids
  • stearic acid
  • Eicosapentaenoic Acid
  • docosapentaenoic acid
Topics
  • Aged
  • Case-Control Studies
  • Eicosapentaenoic Acid (blood)
  • Fatty Acids (blood)
  • Fatty Acids, Unsaturated (blood)
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Odds Ratio
  • Prospective Studies
  • Prostatic Neoplasms (blood)
  • Risk Assessment
  • Risk Factors
  • Stearic Acids (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: